Group 1 - The core point of the article is the strategic cooperation framework agreement signed between Hainan Haiyao and Malaysia's Aikang International Group, which includes exclusive agency cooperation for health products in mainland China [1] - Hainan Haiyao will act as the exclusive agent for Aikang Group's health products in mainland China, indicating a significant market expansion opportunity for the company [1] - The agreement also focuses on market development, aiming to promote Hainan Haiyao's traditional Chinese medicine products into the Malaysian market, which could enhance the company's international presence [1] Group 2 - The partnership includes brand co-building and market promotion efforts to enhance the brand influence of both companies' products, suggesting a collaborative approach to marketing [1] - A cooperation mechanism will be established, including meeting protocols and joint working groups, which indicates a structured approach to the partnership [1] - The agreement is effective for five years from the date of signing, providing a long-term framework for collaboration between the two companies [1]

Group 1: Collaboration and Research Development - The company collaborates with China Pharmaceutical University to establish a joint laboratory focused on innovative and generic drug development, aiming to enhance the scientific reliability and authority of new drug research [2] - The joint laboratory is currently in the early stages of drug screening and optimization, working on clinical candidate discovery and the establishment of an in vitro bioactivity evaluation platform [2] Group 2: Clinical Trials and Drug Development - The company is conducting Phase IIa clinical trials for the drug Paenagabin, with 70 cases enrolled in Phase Ia and 20 cases in Phase Ib [4] - Paenagabin is positioned as a me-better drug compared to Retigabine, which was withdrawn from the market due to stability and safety issues; Paenagabin shows higher activity and better distribution in the brain [3] - The company plans to expand the indications for Paenagabin based on Phase II clinical results and market demand, potentially including severe depression caused by KCNQ mutations [3][4] Group 3: Future Prospects and Market Strategy - The company anticipates entering Phase III clinical trials for the drug Fluorofenidone in the second half of 2025, which has been included in the list of breakthrough therapies by the National Medical Products Administration [5] - Fluorofenidone is expected to expand its indications to include patients with liver fibrosis caused by metabolic liver diseases, depending on clinical trial outcomes [5][6] Group 4: Shareholder Information - The reduction of shares by Yunnan International Trust is a passive action based on prior agreements and will not affect the company's long-term operations and development [6]

Group 1: Financial Performance and Strategy - The company aims to achieve profitability by enhancing R&D efforts and accelerating the launch of new products, with a focus on collaboration with universities and research institutions [1][2] - The company plans to optimize its international business management and deepen market penetration in Southeast Asia, Africa, and Latin America, enhancing its international operational capabilities [2][7] - The company is committed to reducing operational costs through strict budget management and cost-cutting measures [2][7] Group 2: Product Development and Clinical Trials - The company is advancing the clinical trials of its drugs, with the fluorofenone capsule expected to enter Phase III trials in the second half of 2025, having met its primary research endpoints in Phase II [4] - The company is conducting Phase IIa clinical research for the pain relief drug, with ongoing patient recruitment for different dosage cohorts [4][6] - The company is focusing on building a comprehensive product pipeline in the neuropsychiatric field and enhancing its traditional Chinese medicine offerings [3] Group 3: Market Challenges and Responses - The company has experienced a significant decline in sales revenue due to a slowing pharmaceutical market and economic conditions [6][7] - The company is actively participating in national procurement initiatives to maximize market potential and is focusing on key products and markets to drive growth [6][7] - The company acknowledges the challenges posed by strict regulatory requirements in drug approval processes, particularly for new epilepsy medications [5][6]

Group 1 - Longjiang Transportation plans to reduce its shareholding by no more than 3% of the company's total shares, amounting to 39.4764 million shares, from June 4, 2025, to September 3, 2025 [1] - Shuangyi Technology intends to acquire 100% equity of Marky Industries Pty Ltd and specific assets for approximately AUD 18 million [1] - Haikong Air Conditioning's controlling shareholder has received a bank loan commitment of up to CNY 32 million for share repurchase [2] Group 2 - Zhaowei Electromechanical's shareholder plans to reduce its stake by no more than 1.50%, equating to 3.6031 million shares, from June 5, 2025, to September 4, 2025 [2] - Zhongwen Online's directors and senior management plan to collectively reduce their holdings by no more than 877,100 shares, representing 0.1203% of the total shares [2] - Liding Optoelectronics' shareholders plan to reduce their holdings by no more than 3%, totaling 12.2113 million shares, from June 5, 2025, to September 4, 2025 [4] Group 3 - Luvi Optoelectronics' shareholder plans to reduce its stake by no more than 1%, amounting to 1.9333 million shares, from June 4, 2025, to September 4, 2025 [5] - Jiejia Weichuang's controlling shareholder and concerted parties plan to reduce their holdings by no more than 0.72%, totaling 250,000 shares [7] - Yancoal Energy will no longer acquire control of Highfield Resources due to a new investment from Qinghai Salt Lake Industry Co., Ltd. [9] Group 4 - Yongdong Co., Ltd. plans to reduce its shareholding by no more than 1.26%, equating to 473,380 shares, from June 5, 2025, to September 4, 2025 [11] - Sanqi Interactive Entertainment plans to distribute a cash dividend of CNY 2.10 per 10 shares [12] - Salt Lake Co., Ltd. intends to acquire Highfield Resources for approximately USD 300 million to become its largest shareholder [13] Group 5 - Hainan Haiyao's shareholder plans to reduce its stake by no more than 3%, totaling 38.921 million shares, within 90 days after the announcement [14] - Lifang Pharmaceutical plans to transfer 2.2184% equity of Nanjing Mainowei Pharmaceutical Technology Co., Ltd. for CNY 22.1837 million [16] - Zhiyou Technology's shareholders plan to reduce their holdings by no more than 2.99%, totaling 11.9986 million shares, from June 4, 2025, to September 3, 2025 [18] Group 6 - Puli Tui has applied for a review of the Shenzhen Stock Exchange's decision to terminate its listing [19] - Saimo Intelligent's shareholder plans to reduce its stake by no more than 3%, equating to 16.0659 million shares, from June 4, 2025, to September 3, 2025 [20] - Entropy Technology is planning to acquire 55% equity of Longzhiyuan to gain control [21] Group 7 - Nanjing Chemical Fiber plans to acquire 100% of Nanjing Process Equipment Manufacturing Co., Ltd. through asset swaps and cash payments [22] - Beijing Lier intends to invest CNY 200 million in Shanghai Zhenliang Intelligent Technology Co., Ltd. [23]

Economic Information - In April, the housing rental industry entered a low season, with the average residential rent in 50 cities decreasing by 0.32% month-on-month to 35.2 yuan per square meter per month, and a year-on-year decline of 3.40% [2] - The global N-type SiC substrate industry is expected to see a revenue decrease of 9% in 2024, amounting to $1.04 billion, due to weakened automotive and industrial demand, increased market competition, and significant price drops [2] Company Alerts - Spring光科技 has announced that its stock is subject to irrational market speculation risk [3] - 博云新材's shareholder 高创投 plans to reduce its stake by no more than 3% [3] - Other companies such as 龙江交通, 海南海药, and 赛摩智能 also have shareholders planning to reduce their stakes by up to 3% [3][5] Overseas Market Alerts - COMEX gold futures fell by 2.76% to $3,240.1 per ounce, while silver futures decreased by 0.42% to $32.775 per ounce [2] - Citigroup forecasts that gold will consolidate in the range of $3,000 to $3,300 per ounce in the coming months, adjusting its 0-3 month target price to $3,150 per ounce [2] - Russia's oil production is expected to recover to 10.8 million barrels per day due to global demand growth and changes in domestic investment and taxation [3]

公司持股 5%以上股东云南国际信托有限公司－聚利 36 号单一资金信托保证 向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 证券代码：000566 证券简称：海南海药 公告编号：2025-038 海南海药股份有限公司 关于持股 5%以上股东减持股份的预披露公告 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有海南海药股份有限公司（简称"本公司"）股份 107,216,412 股（占本 公司总股本比例 8.26%）的股东云南国际信托有限公司－聚利 36 号单一资金信 托（简称"云南国际信托"）计划在本公告披露之日起 15 个交易日后的连续 90 个自然日内以集中竞价和大宗交易方式合计减持本公司股份不超过 38,920,953 股，占本公司总股本的 3%；其中，通过集中竞价交易减持不超过 12,973,651 股 （占本公司总股本比例 1%）；通过大宗交易方式减持不超过 25,947,302 股（占 本公司总股本比例 2%）。 一、减持主体的基本情况 二、本次减持计划的主要内容 （一）云南国际信托拟减持的具体安排 股、资本公积金转增股本等股份变动 ...

4.央行等联合印发《关于金融支持广州南沙深化面向世界的粤港澳全面合作的意见》 近日，中国人民银行、金融监管总局、中国证监会、国家外汇局、广东省人民政府联合印发《关于金融 支持广州南沙深化面向世界的粤港澳全面合作的意见》（以下简称《意见》）。《意见》从完善创新创 业金融服务、加强社会民生领域金融服务、发展特色金融服务、推进粤港澳金融市场互联互通、开展跨 境金融创新与交流、完善金融监管机制等方面提出30条重点举措，推动广州南沙在粤港澳大湾区"新发 展格局战略支点、高质量发展示范地、中国式现代化引领地"建设中更好发挥引领带动作用。 5.广东发布《金融支持促消费扩内需专项行动方案》 重要的消息有哪些 1.中美日内瓦经贸会谈联合声明 双方承诺将于2025年5月14日前采取以下举措：美国将（一）修改2025年4月2日第14257号行政令中规定 的对中国商品（包括香港特别行政区和澳门特别行政区商品）加征的从价关税，其中，24%的关税在初 始的90天内暂停实施，同时保留按该行政令的规定对这些商品加征剩余10%的关税；（二）取消根据 2025年4月8日第14259号行政令和2025年4月9日第14266号行政令对这些商品的加征 ...

关于持股 5%以上股东减持股份的预披露公告 公司持股 5%以上股东云南国际信托有限公司－聚利 36 号单一资金信托保证 向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 持有海南海药股份有限公司（简称"本公司"）股份 107,216,412 股（占本 公司总股本比例 8.26%）的股东云南国际信托有限公司－聚利 36 号单一资金信 托（简称"云南国际信托"）计划在本公告披露之日起 15 个交易日后的连续 90 个自然日内以集中竞价和大宗交易方式合计减持本公司股份不超过 38,920,953 股，占本公司总股本的 3%；其中，通过集中竞价交易减持不超过 12,973,651 股 （占本公司总股本比例 1%）；通过大宗交易方式减持不超过 25,947,302 股（占 本公司总股本比例 2%）。 一、减持主体的基本情况 1、股东名称：云南国际信托有限公司－聚利 36 号单一资金信托 证券代码：000566 证券简称：海南海药 公告编号：2025-038 2、股东持股情况：截至本公告日，云南国际信托持有本公司股份 107 ...

金十数据5月12日讯，海南海药公告，持股5%以上股东云南国际信托有限公司-聚利36号单一资金信托 计划在公告披露之日起15个交易日后的连续90个自然日内，以集中竞价和大宗交易方式合计减持公司股 份不超过3892.1万股，占公司总股本的3%。 海南海药：云南国际信托拟减持不超3%公司股份 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-037 海南海药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、特别提示： 二、会议召开的情况 现场会议召开时间：2025年5月9日下午15：00 网络投票时间：2025年5月9日 （1）通过深圳证券交易所交易系统进行网络投票的时间为：2025 年5月9日9：15～ （2）通过深圳证券交易所互联网投票系统投票的时间为2025年5月9日9:15～15:00 期间的任意时间。 北京大成(海口)律师事务所见证律师对本次股东大会进行见证，并出具法律意见书。 《关于召开 2024 年年度股东大会的通知》，本次股东大会的内容及大会召集、召开方式、 程序均符合《公司法》《股票上市规则》及《公司章程》的有关规定。 三、会议的出席情况 本次股东大会以现场投票和网络投票相结合的表决方式对列入会议审议的议案进 行了表决，具体表决结果如下： （一）审议通过了《关于 2024 年度董事会工作报告的议案》 总表决情况： 同意 427,102,481 股，占出席会议所有股东所持表决权股份的 99.8218%； ...